BioSpace News Archive

Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today provided a financial and corporate update in conjunction with the Company’s 10-Q filing for the quarter ended March 31, 2023.

Vibrant Gastro, a medical technology company that developed an FDA-cleared drug-free treatment for chronic idiopathic constipation (CIC) in adults, presented an abstract at the 2023 Digestive Disease Week Conference in Chicago.

Acasti Pharma Inc. today announced the successful submission to the FDA of GTX-104’s full protocol of its pivotal Phase 3 Safety Study and implementation of a strategic realignment plan to maximize shareholder value.

Ginkgo Bioworks today announced a new partnership with Boehringer Ingelheim.

REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences.

Deciphera Pharmaceuticals, Inc. today announced that members of the management team will participate in a fireside chat at the JMP Securities Life Sciences Conference on Monday, May 15, 2023 at 2:30 PM ET in New York, NY.

CareDx, Inc. today announced it will report financial results for the first quarter 2023 after market close on Wednesday, May 10, 2023.

Vedanta Biosciences today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to Vedanta’s defined bacterial consortium candidate, VE303, for the prevention of recurrent Clostridioides difficile infection (rCDI).

Bruker Announces Acquisition of ZONTAL to Advance the Digital Laboratory Transformation and Integrated Biopharma Data Solutions.

OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its first quarter 2023 financial results after the close of the U.S. financial markets on Monday, May, 15th , 2023.